OBJECTIVE:To compare the economical effects of miglitol and acarbose in the treatment of type 2diabetes.METHODS:Totally 100 patients with type 2 diabetes admitted into No.910th Hospital of PLA from Sept.2017 to Aug.2018 were extracted to be divided into the miglitol group and the acarbose group via the admission sequence

with 50 cases in each group.The miglitol group was treated orally with miglitol

while the acarbose group received acarbose.Both groups were additionally given metformin

the course of treatment was 12 weeks.Clinical efficacy such as fasting blood glucose（FBG）

2 h postprandial blood glucose（2 h PBG）

glycated hemoglobin（HbA

1

c）

the levels of FBG

2 h PBG and HbA

1

c of two groups were observed before and after treatment

costeffectiveness analysis was performed by using pharmacoeconomics principles.RESULTS:After treatment of 12 weeks

the levels of FBG

2 h PBG and HbA

1

c in two groups were significantly lower than those before treatment

and the levels of the above indicators in the miglitol group were significantly lower than those in the acarbose group

the differences were statistically significant（P

<

0.05）.The C/E of the three indicators of the miglitol group were lower than those of the acarbose group

and theΔC/ΔE of the acarbose group to the miglitol group was 26.04

39.06 and11.16

respectively.The incidence of adverse drug reactions in the miglitol group and the acarbose group was 4.0%（2/50）and 8.0%（4/50）

respectively

with no significant difference（P

>

0.05）.CONCLUSIONS:Miglitol can significantly reduce the levels of FBG

2 h PBG and HbA

1

c in patients with type 2 diabetes

with significant clinical efficacy

fewer adverse drug reactions and higher advantages of pharmacoeconomics.